Page 76 - Haematologica-5

808
M. Schneeweiss et al.
DCC-2618 required to block tryptase secretion in MC were rather low (<1.0 μM), the concentrations required to block IgE-dependent histamine release were rather high (1 μM).
Collectively, our data indicate that DCC-2618 is a novel promising agent that counteracts growth and survival of various cell types relevant to the pathogenesis of advanced SM. Whether DCC-2618 is able to block
growth of neoplastic MC in patients with advanced SM is currently being explored in a clinical trial (NCT02571036).
Acknowledgments
This study was supported by a grant from Deciphera Pharmaceuticals LLC. We like to thank Dr. Dan Flynn, Dr. Bryan Smith and Dr. Oliver Rosen for helpful discussion.
References
1. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 1991;96(3):2S-4S.
2. Valent P. Biology, classification and treat- ment of human mastocytosis. Wien Klin Wochenschr. 1996;108(13):385-397.
3. Horny HP, Valent P. Diagnosis of mastocy- tosis: general histopathological aspects, morphological criteria, and immunohisto- chemical findings. Leuk Res. 2001;25(7): 543-551.
4. Escribano L, Akin C, Castells M, et al. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002;81(12): 677-690.
5. Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003;122(5): 695-717.
6. Akin C, Metcalfe DD. Systemic mastocyto- sis. Annu Rev Med. 2004;55:419-432.
7. Arock M, Valent P. Pathogenesis, classifica- tion and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol. 2010;3(4):497-516.
8. Valent P, Horny H-P, Escribano L, et al. Diagnostic criteria and classification of mas- tocytosis: a consensus proposal. Leuk Res. 2001;25(27):603-625.
9. Valent P, Horny H-P, Li CY, et al. Mastocytosis (mast cell disease). World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Eds: Jaffe ES, Harris NL, Stein H, Vardiman JW 2001;1:291-302.
10. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classifi- cation and novel emerging treatment con- cepts. Blood. 2017;129(11):1420-1427.
11. Horny HP, Akin C, Arber D, et al. Mastocytosis. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Eds: Swerdlow SH, Campo E, Harris NL et al. IARC Press Lyon, France, vol 3, pp 62-69, 2017(2):62-69.
12. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: sur- vival studies and prognostic factors. Blood. 2009;113(23):5727-5736.
13. Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associ- ated with other myeloid malignancies. Blood. 2009;114(18):3769-3772.
14. Escribano L, Alvarez-Twose I, Sánchez- Muñoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009;124(3):514-521.
15. Valent P, Akin C, Sperr WR, et al. Aggressive
systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003;27(7):635-641.
16. Arock M, Akin C, Hermine O, et al. Current treatment options in patients with mastocy- tosis: status in 2015 and future perspectives. Eur J Haematol. 2015;94(6):474-490.
17. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J Clin Invest. 1993;92(4):1736- 1744.
18. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the cat- alytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci. 1995;92(23):10560-10564.
19. Feger F, Ribadeau Dumas A, et al. Kit and c- kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol. 2002;127(2):110-114.
20. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c- kit activating mutation in urticaria pigmen- tosa and aggressive mastocytosis: establish- ment of clonality in a human mast cell neo- plasm. Nat Genet. 1996;12(3):312-314.
21. Fritsche-Polanz R, Jordan JH, Feix A, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mas- tocytosis and cases of systemic mastocyto- sis. Br J Haematol. 2001;113(2):357-364.
22. Arock M, Sotlar K, Akin C, et al. KIT muta- tion analysis in mast cell neoplasms: recom- mendations of the European Competence Network on Mastocytosis. Leukemia. 2015;29(6):1223-1232.
23. Shah NP, Lee FY, Luo R, et al. Dasatinib (BMS-354825) inhibits KITD816V, an ima- tinib-resistant activating mutation that trig- gers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006;108(1):286-291.
24. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol. 2003;31(8):686-692.
25. Gleixner KV, Mayerhofer M, Sonneck K, et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica. 2007;92(11):1451-1459.
26. Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine
(2CdA) and evaluation of cooperative drug
effects. Blood. 2006;107(2):752-759.
27. Fabbro D, Ruetz S, Bodis S, et al. PKC412 — a protein kinase inhibitor with a broad ther- apeutic potential. Anticancer Drug Des.
2000;15(1):17-28.
28. Gotlib J, Kluin-Nelemans HC, George TI, et
al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530-2541.
29. Gotlib J, Berubé C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106(8):2865-2870.
30. Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol. 2002;127(2):140-142.
31. Horny HP, Sotlar K, Sperr WR, et al. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol. 2004;57(6):604-608.
32. Pardanani A. Systemic mastocytosis in adults: 2017 update on diagnosis, risk strat- ification and management. Am J Hematol. 2016;91(11):1146-1159.
33. Pardanani A, Reeder T, Li CY, et al. Eosinophils are derived from the neoplastic clone in patients with systemic mastocyto- sis and eosinophilia. Leuk Res. 2003;27(10): 883-885.
34. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1- PDGFRA fusion, occurs in systemic masto- cytosis associated with eosinophilia and predicts response to imatinib mesylate ther- apy. Blood. 2003;102(9):3093-3096.
35. Smith BD, Hood MM, Wise SC, et al. DCC- 2618 is a potent inhibitor of wild-type and mutant KIT, including refractory exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models. Cancer Res. 2015;75(15): abstract 2690.
36. Bai Y, Bandara G, Ching Chan E, et al, Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neo- plastic mast cell proliferation and mast cell activation. Leukemia. 2013; 27(2):278-285.
37. Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1988;12(4):345-355.
38. Saleh R, Wedeh G, Herrmann H, et al., A new human mast cell line expressing a func- tional IgE receptor converts to factor-inde- pendence and tumorigenicity by KIT D816V-transfection. Blood. 2014;124(1): 111-120.
39. Hoermann G, Blatt K, Greiner G, et al., CD52 is a molecular target in advanced sys- temic mastocytosis. FASEB J. 2014;28(8):
haematologica | 2018; 103(5)